BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN), today announced that on March 27, 2008, it received a warning letter from the American Stock Exchange (“Amex”) citing a minor violation in connection with the company’s recently announced private placement of securities completed on February 29, 2008, of Section 301 of the Amex Company Guide, which provides that a listed company may not issue, or authorize its transfer agent or registrar to issue or register, additional securities of a listed class until it has filed an application for the listing of such additional securities and received notification from Amex that the securities have been approved for listing. The company filed an application on March 21, 2008, for the listing of the additional securities referenced in the notification from Amex. As of the date hereof, the company had not yet received approval to list the additional shares although it expects to receive such approval upon completion of the application review by Amex within approximately two weeks.
